In lung cancer, levels of IgG1 and IgG3 antibodies are positively correlated with CD16a expression, suggesting that increased levels of these subclasses may enhance NK cell activation, as CD16a is a key activating receptor on NK cells (77). The gene discussed is FCGR3A; the disease is lung carcinoma.